A detailed history of Wellington Management Group LLP transactions in Genmab A/S stock. As of the latest transaction made, Wellington Management Group LLP holds 2,306,920 shares of GMAB stock, worth $53.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,306,920
Previous 2,331,814 1.07%
Holding current value
$53.3 Million
Previous $69.7 Million 16.88%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$25.13 - $30.27 $625,586 - $753,541
-24,894 Reduced 1.07%
2,306,920 $58 Million
Q1 2024

May 15, 2024

BUY
$26.43 - $32.77 $61.6 Million - $76.4 Million
2,331,814 New
2,331,814 $69.7 Million
Q4 2023

Feb 12, 2024

BUY
$27.94 - $35.44 $66.2 Million - $84 Million
2,369,331 New
2,369,331 $75.4 Million
Q3 2023

Nov 14, 2023

BUY
$35.27 - $42.24 $290,765 - $348,226
8,244 Added 0.34%
2,425,381 $85.5 Million
Q2 2023

Aug 14, 2023

SELL
$37.4 - $42.94 $141,484 - $162,442
-3,783 Reduced 0.16%
2,417,137 $91.9 Million
Q1 2023

May 12, 2023

SELL
$34.88 - $43.22 $416,781 - $516,435
-11,949 Reduced 0.49%
2,420,920 $91.4 Million
Q4 2022

Feb 13, 2023

SELL
$33.8 - $47.06 $31.4 Million - $43.7 Million
-928,842 Reduced 27.63%
2,432,869 $103 Million
Q3 2022

Nov 14, 2022

SELL
$31.52 - $373.61 $154,983 - $1.84 Million
-4,917 Reduced 0.15%
3,361,711 $108 Million
Q2 2022

Aug 15, 2022

BUY
$26.83 - $38.57 $880,131 - $1.27 Million
32,804 Added 0.98%
3,366,628 $109 Million
Q1 2022

May 16, 2022

BUY
$30.95 - $39.68 $5.68 Million - $7.28 Million
183,578 Added 5.83%
3,333,824 $121 Million
Q4 2019

Feb 11, 2020

BUY
$18.88 - $24.14 $59.5 Million - $76 Million
3,150,246 New
3,150,246 $70.3 Million

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $15.2B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.